Printer Friendly

Antipsychotic Drugs Market to Reach USD 14.4bn by 2025, Research and Markets Forecasts.

M2 PHARMA-March 30, 2017-Antipsychotic Drugs Market to Reach USD 14.4bn by 2025, Research and Markets Forecasts

(C)2017 M2 COMMUNICATIONS

- The global antipsychotic drugs market is expected to reach USD 14.4bn by 2025, according to a new report from Dublin-based Research and Markets.

Continuous development of better next-generation products to overcome adverse effects and unwanted reactions of existing products is creating demand for newer products.

This factor is anticipated to propel the market.

Rapid growth of antipsychotics can be attributed to the rising prevalence of psychosis and other mental disorders.

Governments are focused on creating awareness regarding mental health and psychological illnesses, which is further anticipated to drive the demand for antipsychotics.

Government bodies in collaboration with major players conduct social programs to break the stigma related to psychotic disorders that exists in the society.

Adverse effects of antipsychotics, such as insomnia, dry mouth, drowsiness, and blurred vision, are expected to affect the growth by decreasing the level of acceptance in patients.

In addition, the possibility of dependency, habit formation, or addiction is affecting the adoption of these drugs.

Key players in this market include Johnson and Johnson, Pfizer, Inc., Eli Lilly and Co., Bristol-Myers Squibb Co, AstraZeneca, Glaxo SmithKline, Plc and Allergan.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Mar 30, 2017
Words:216
Previous Article:IncellDx Launches CE-Marked OncoTect iO Lung Kit.
Next Article:Spectrum Pharmaceuticals Launches Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters